Loading stock data…
Prime Medicine (PRME)
$3.56-0.14 (-3.78%)
Market ClosedLast close Sep 8
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Prime Medicine, Inc. in the Healthcare sector is trading at $3.56 with a market capitalization of $516M. Wall Street consensus targets $7.11 (11 analysts), implying a +99.8% move over the next 12 months. The stock is currently 49% below its 52-week high of $6.94, remaining 0.3% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +99.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $856,000↑ | $838,000↓ | $1.23M↑ | $1.11M↓ | $1.45M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$50.65M↓ | -$48.61M↑ | -$53.97M↓ | -$53.38M↓ | -$52.39M |
| Net Income | -$49.12M↓ | -$46.08M↑ | -$50.58M↑ | -$52.59M↓ | -$51.89M |
Peer Comparison
JNJUNHPFE
Fundamentals
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulom...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$515.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-258.64%
Volume
Today's trading volume
3.60M
Recent News
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of 0.00% and -73.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Scribe’s Genetic Editing Aims to Prevent Heart Attacks
Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and strokes. Scribe’s therapies turn off the genetic instructions leading to high levels of damaging lipids, without having to cut a gene’s DNA strands like other one-shot genetic treatments in the clinic.
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM)
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 10 affordable biotech stocks to buy right now. On July 8, Alec Stranahan from Bank of America Securities reaffirmed his Buy rating for Beam Therapeutics Inc. (NASDAQ:BEAM), following a favorable resolution announced by Prime Medicine regarding its arbitration with Beam. Stranahan forecasted a target price of $47, […]
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics
Prime Medicine, Inc. (NASDAQ:PRME) is one of the best strong buy penny stocks to invest in now. Prime Medicine, Inc. (NASDAQ:PRME) announced on July 8 a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, Inc. relating to the parties’ 2019 Collaboration and License Agreement. The company reported that the Tribunal declared that PM647, […]